Administration of recombinant human GM-CSF (rhGM-CSF) can benefit patients undergoing bone marrow transplantation by promoting faster hematopoietic reconstitution and enhancing the ability of macrophages to combat infections and tumor cells (60). This evidence concerns the gene CSF2 and neoplasm.